A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

NCT04392700 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

706

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Recurrent

Interventions

DRUG: Tenofovir disoproxil fumarate 300mg
DRUG: Entecavir 0.5 mg

Sponsor

Sun Yat-sen University